John R. Seavitt
Baylor College of Medicine
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by John R. Seavitt.
Nature | 2016
Mary E. Dickinson; Ann M. Flenniken; Xiao Ji; Lydia Teboul; Michael D. Wong; Jacqueline K. White; Terrence F. Meehan; Wolfgang J. Weninger; Henrik Westerberg; Hibret Adissu; Candice N. Baker; Lynette Bower; James Brown; L. Brianna Caddle; Francesco Chiani; Dave Clary; James Cleak; Mark J. Daly; James M. Denegre; Brendan Doe; Mary E. Dolan; Sarah M. Edie; Helmut Fuchs; Valérie Gailus-Durner; Antonella Galli; Alessia Gambadoro; Juan Gallegos; Shiying Guo; Neil R. Horner; Chih-Wei Hsu
Approximately one-third of all mammalian genes are essential for life. Phenotypes resulting from knockouts of these genes in mice have provided tremendous insight into gene function and congenital disorders. As part of the International Mouse Phenotyping Consortium effort to generate and phenotypically characterize 5,000 knockout mouse lines, here we identify 410 lethal genes during the production of the first 1,751 unique gene knockouts. Using a standardized phenotyping platform that incorporates high-resolution 3D imaging, we identify phenotypes at multiple time points for previously uncharacterized genes and additional phenotypes for genes with previously reported mutant phenotypes. Unexpectedly, our analysis reveals that incomplete penetrance and variable expressivity are common even on a defined genetic background. In addition, we show that human disease genes are enriched for essential genes, thus providing a dataset that facilitates the prioritization and validation of mutations identified in clinical sequencing efforts.
Nature Genetics | 2017
Terrence F. Meehan; Nathalie Conte; David B. West; Julius Jacobsen; Jeremy Mason; Jonathan Warren; Chao Kung Chen; Ilinca Tudose; Mike Relac; Peter Matthews; Natasha A. Karp; Luis Santos; Tanja Fiegel; Natalie Ring; Henrik Westerberg; Simon Greenaway; Duncan Sneddon; Hugh Morgan; Gemma F. Codner; Michelle Stewart; James Brown; Neil R. Horner; Melissa Haendel; Nicole L. Washington; Christopher J. Mungall; Corey Reynolds; Juan Gallegos; Valerie Gailus-Durner; Tania Sorg; Guillaume Pavlovic
Although next-generation sequencing has revolutionized the ability to associate variants with human diseases, diagnostic rates and development of new therapies are still limited by a lack of knowledge of the functions and pathobiological mechanisms of most genes. To address this challenge, the International Mouse Phenotyping Consortium is creating a genome- and phenome-wide catalog of gene function by characterizing new knockout-mouse strains across diverse biological systems through a broad set of standardized phenotyping tests. All mice will be readily available to the biomedical community. Analyzing the first 3,328 genes identified models for 360 diseases, including the first models, to our knowledge, for type C Bernard–Soulier, Bardet–Biedl-5 and Gordon Holmes syndromes. 90% of our phenotype annotations were novel, providing functional evidence for 1,092 genes and candidates in genetically uncharacterized diseases including arrhythmogenic right ventricular dysplasia 3. Finally, we describe our role in variant functional validation with The 100,000 Genomes Project and others.
Nature Communications | 2017
Natasha A. Karp; Jeremy Mason; Arthur L. Beaudet; Yoav Benjamini; Lynette Bower; Robert E. Braun; Steve D.M. Brown; Elissa J. Chesler; Mary E. Dickinson; Ann M. Flenniken; Helmut Fuchs; Martin Hrabé de Angelis; Xiang Gao; Shiying Guo; Simon Greenaway; Ruth Heller; Yann Herault; Monica J. Justice; Natalja Kurbatova; Christopher J. Lelliott; K. C. Kent Lloyd; Ann-Marie Mallon; Judith E. Mank; Hiroshi Masuya; Colin McKerlie; Terrence F. Meehan; Richard F. Mott; Stephen A. Murray; Helen E. Parkinson; Ramiro Ramirez-Solis
The role of sex in biomedical studies has often been overlooked, despite evidence of sexually dimorphic effects in some biological studies. Here, we used high-throughput phenotype data from 14,250 wildtype and 40,192 mutant mice (representing 2,186 knockout lines), analysed for up to 234 traits, and found a large proportion of mammalian traits both in wildtype and mutants are influenced by sex. This result has implications for interpreting disease phenotypes in animal models and humans.
Nature Communications | 2017
Michael R. Bowl; Michelle Simon; Neil J. Ingham; Simon Greenaway; Luis Santos; Heather Cater; Sarah Taylor; Jeremy Mason; Natalja Kurbatova; Selina Pearson; Lynette Bower; Dave Clary; Hamid Meziane; Patrick Reilly; Osamu Minowa; Lois Kelsey; Glauco P. Tocchini-Valentini; Xiang Gao; Allan Bradley; William C. Skarnes; Mark W. Moore; Arthur L. Beaudet; Monica J. Justice; John R. Seavitt; Mary E. Dickinson; Wolfgang Wurst; Martin Hrabé de Angelis; Yann Herault; Shigeharu Wakana; Lauryl M. J. Nutter
The developmental and physiological complexity of the auditory system is likely reflected in the underlying set of genes involved in auditory function. In humans, over 150 non-syndromic loci have been identified, and there are more than 400 human genetic syndromes with a hearing loss component. Over 100 non-syndromic hearing loss genes have been identified in mouse and human, but we remain ignorant of the full extent of the genetic landscape involved in auditory dysfunction. As part of the International Mouse Phenotyping Consortium, we undertook a hearing loss screen in a cohort of 3006 mouse knockout strains. In total, we identify 67 candidate hearing loss genes. We detect known hearing loss genes, but the vast majority, 52, of the candidate genes were novel. Our analysis reveals a large and unexplored genetic landscape involved with auditory function.The full extent of the genetic basis for hearing impairment is unknown. Here, as part of the International Mouse Phenotyping Consortium, the authors perform a hearing loss screen in 3006 mouse knockout strains and identify 52 new candidate genes for genetic hearing loss.
American Journal of Human Genetics | 2017
Teresa Santiago-Sim; Lindsay C. Burrage; Frédéric Ebstein; Mari Tokita; Marcus J. Miller; Weimin Bi; Alicia Braxton; Jill A. Rosenfeld; Maher Shahrour; Andrea Lehmann; Benjamin Cogné; Sébastien Küry; Thomas Besnard; Bertrand Isidor; Stéphane Bézieau; Isabelle Hazart; Honey Nagakura; Ladonna Immken; Rebecca Okashah Littlejohn; Elizabeth Roeder; Zaid Afawi; Rudi Balling; Nina Barišić; Stéphanie Baulac; Dana Craiu; Peter De Jonghe; Rosa Guerrero-López; Renzo Guerrini; Ingo Helbig; Helle Hjalgrim
Ubiquitination is a posttranslational modification that regulates many cellular processes including protein degradation, intracellular trafficking, cell signaling, and protein-protein interactions. Deubiquitinating enzymes (DUBs), which reverse the process of ubiquitination, are important regulators of the ubiquitin system. OTUD6B encodes a member of the ovarian tumor domain (OTU)-containing subfamily of deubiquitinating enzymes. Herein, we report biallelic pathogenic variants in OTUD6B in 12 individuals from 6 independent families with an intellectual disability syndrome associated with seizures and dysmorphic features. In subjects with predicted loss-of-function alleles, additional features include global developmental delay, microcephaly, absent speech, hypotonia, growth retardation with prenatal onset, feeding difficulties, structural brain abnormalities, congenital malformations including congenital heart disease, and musculoskeletal features. Homozygous Otud6b knockout mice were subviable, smaller in size, and had congenital heart defects, consistent with the severity of loss-of-function variants in humans. Analysis of peripheral blood mononuclear cells from an affected subject showed reduced incorporation of 19S subunits into 26S proteasomes, decreased chymotrypsin-like activity, and accumulation of ubiquitin-protein conjugates. Our findings suggest a role for OTUD6B in proteasome function, establish that defective OTUD6B function underlies a multisystemic human disorder, and provide additional evidence for the emerging relationship between the ubiquitin system and human disease.
Developmental Biology | 2016
Chih-Wei Hsu; Leeyean Wong; Tara L. Rasmussen; Sowmya Kalaga; Melissa L. McElwee; Lance C. Keith; Ritu Bohat; John R. Seavitt; Arthur L. Beaudet; Mary E. Dickinson
In this work, we report the use of iodine-contrast microCT to perform high-throughput 3D morphological analysis of mouse embryos and neonates between embryonic day 8.5 to postnatal day 3, with high spatial resolution up to 3 μm/voxel. We show that mouse embryos at early stages can be imaged either within extra embryonic tissues such as the yolk sac or the decidua without physically disturbing the embryos. This method enables a full, undisturbed analysis of embryo turning, allantois development, vitelline vessels remodeling, yolk sac and early placenta development, which provides increased insights into early embryonic lethality in mutant lines. Moreover, these methods are inexpensive, simple to learn and do not require substantial processing time, making them ideal for high throughput analysis of mouse mutants with embryonic and early postnatal lethality.
Nature Methods | 2018
Lauryl M. J. Nutter; Jason D. Heaney; K. C. Kent Lloyd; Stephen A. Murray; John R. Seavitt; William C. Skarnes; Lydia Teboul; Steve D.M. Brown; Mark Moore
untreated embryos from the same embryo pool. Without specific information about the genetic relationship between the control and F0 animals, one can attribute all the mutations observed to genetic drift between independently bred mouse colonies or commercial strains over time. There have been three other published studies using next-generation sequencing for the unbiased examination of Cas9 off-target mutations in mouse model production6-8. None of these studies identified significant off-target activity. Two of these studies, one using Cas9 nickase6 and one using Cas9 endonuclease8, carefully assessed SNVs, and neither study observed SNVs that could not be attributed to either the parental colony or genetic drift within the colony used for embryo production. Importantly, the number of indels that could be attributed to Cas9 was also very small, <1 per founder, on average7,8. Despite this overwhelming evidence to the contrary, Schaefer et al. offer no explanation of their conflicting outcome. The International Mouse Phenotyping Consortium (IMPC) agrees with the editors of Nature Methods9 that standardization of approaches to experimental design and quality control using Cas9, or indeed any genome-editing tool, are vitally important, both to the future clinical applications of Cas9 and to the production of mouse models using Cas9. Only with excellent quality assurance during production and quality control of derived mouse lines can we have confidence in our ability to generate reliable and reproducible data.
American Journal of Medical Genetics Part A | 2016
Magalie S. Leduc; Zhiyv Niu; Weimin Bi; Wenmiao Zhu; Irene Miloslavskaya; Theodore Chiang; Haley Streff; John R. Seavitt; Stephen A. Murray; Christine M. Eng; Audrey Chan; Yaping Yang; Seema R. Lalani
Mutations in CRIPT encoding cysteine‐rich PDZ domain‐binding protein are rare, and to date have been reported in only two patients with autosomal recessive primordial dwarfism and distinctive facies. Here, we describe a female with biallelic mutations in CRIPT presenting with postnatal growth retardation, global developmental delay, and dysmorphic features including frontal bossing, high forehead, and sparse hair and eyebrows. Additional clinical features included high myopia, admixed hyper‐ and hypopigmented macules primarily on the face, arms, and legs, and syndactyly of 4–5 toes bilaterally. Using whole exome sequencing (WES) and chromosomal microarray analysis (CMA), we detected a c.8G>A (p.C3Y) missense variant in exon 1 of the CRIPT gene inherited from the mother and a 1,331 bp deletion encompassing exon 1, inherited from the father. The c.8G>A (p.C3Y) missense variant in CRIPT was apparently homozygous in the proband due to the exon 1 deletion. Our findings illustrate the clinical utility of combining WES with copy number variant (CNV) analysis to provide a molecular diagnosis to patients with rare Mendelian disorders. Our findings also illustrate the clinical spectrum of CRIPT related mutations.
BMC Biology | 2018
Denise G. Lanza; Angelina Gaspero; Isabel Lorenzo; Lan Liao; Ping Zheng; Ying Wang; Yu Deng; Chonghui Cheng; Chuansheng Zhang; John R. Seavitt; Francesco J. DeMayo; Jianming Xu; Mary E. Dickinson; Arthur L. Beaudet; Jason D. Heaney
BackgroundThe International Mouse Phenotyping Consortium is generating null allele mice for every protein-coding gene in the genome and characterizing these mice to identify gene–phenotype associations. While CRISPR/Cas9-mediated null allele production in mice is highly efficient, generation of conditional alleles has proven to be more difficult. To test the feasibility of using CRISPR/Cas9 gene editing to generate conditional knockout mice for this large-scale resource, we employed Cas9-initiated homology-driven repair (HDR) with short and long single stranded oligodeoxynucleotides (ssODNs and lssDNAs).ResultsUsing pairs of single guide RNAs and short ssODNs to introduce loxP sites around a critical exon or exons, we obtained putative conditional allele founder mice, harboring both loxP sites, for 23 out of 30 targeted genes. LoxP sites integrated in cis in at least one mouse for 18 of 23 genes. However, loxP sites were mutagenized in 4 of the 18 in cis lines. HDR efficiency correlated with Cas9 cutting efficiency but was minimally influenced by ssODN homology arm symmetry. By contrast, using pairs of guides and single lssDNAs to introduce loxP-flanked exons, conditional allele founders were generated for all four genes targeted, although one founder was found to harbor undesired mutations within the lssDNA sequence interval. Importantly, when employing either ssODNs or lssDNAs, random integration events were detected.ConclusionsOur studies demonstrate that Cas9-mediated HDR with pairs of ssODNs can generate conditional null alleles at many loci, but reveal inefficiencies when applied at scale. In contrast, lssDNAs are amenable to high-throughput production of conditional alleles when they can be employed. Regardless of the single-stranded donor utilized, it is essential to screen for sequence errors at sites of HDR and random insertion of donor sequences into the genome.
bioRxiv | 2017
Denise G. Lanza; Angelina Gaspero; Isabel Lorenzo; Lan Liao; Ping Zheng; Ying Wang; Yu Deng; Chonghui Cheng; Chuansheng Zhang; Matthew N. Rasband; John R. Seavitt; Francisco J. DeMayo; Jianming Xu; Mary E. Dickinson; Arthur L. Beaudet; Jason D. Heaney
The International Mouse Phenotyping Consortium is generating null allele mice for every protein-coding gene in the genome and characterizing these mice to identify gene-phenotype associations. To test the feasibility of using CRISPR/Cas9 gene editing to generate conditional knockout mice for this large-scale resource, we employed Cas9-mediated homology driven repair (HDR) with short and long single-stranded oligodeoxynucleotides (ssODNs and lssODNs). Using pairs of guides and ssODNs donating loxP sites, we obtained putative conditional allele founder mice, harboring both loxP sites, for 23 of 30 genes targeted. LoxP sites integrated in cis in at least one F0 for 18 of 23 targeted genes. However, loxP sites were mutagenized in 4 of 18 in cis lines. HDR efficiency correlated with Cas9 cutting efficiency but was not influenced by ssODN homology arm symmetry. By contrast, using pairs of guides and a single lssODN to introduce a loxP-flanked exon, conditional allele founders were generated for all 4 genes targeted. Our studies demonstrate that Cas9-mediated HDR with pairs of ssODNs can generate conditional null alleles at many loci, but reveal inefficiencies when applied at scale. In contrast, lssODNs are amenable to high-throughput production of conditional alleles when they can be employed.